| Bioactivity | SXC2023 is an inhibitor for solute carrier family 7 member 11 (SLC7A11). SXC2023 exhibits antitumor efficacy, and ameliorates central nervous system disorder through downregulation of glutamate export[1]. |
| CAS | 1695562-36-7 |
| Formula | C13H15NO4S |
| Molar Mass | 281.33 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. PENDERGAST AM, et al., Compositions and methods for the treatment cancer and cns disorders. WO2021030783 A1. |
SXC2023
CAS: 1695562-36-7 F: C13H15NO4S W: 281.33
SXC2023 is an inhibitor for solute carrier family 7 member 11 (SLC7A11). SXC2023 exhibits antitumor efficacy, and amelio
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.